A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma

Trial Profile

A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Jul 2017

At a glance

  • Drugs Dalantercept (Primary) ; Axitinib
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms DART
  • Sponsors Acceleron Pharma
  • Most Recent Events

    • 14 Jul 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Sep 2017.
    • 14 Jul 2017 Status changed from recruiting to active, no longer recruiting.
    • 12 Jun 2017 Primary endpoint (Part 2: Progression free survival (PFS) has not been met, according to an Acceleron Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top